<DOC>
	<DOCNO>NCT02797652</DOCNO>
	<brief_summary>Our study aim evaluate possibility clinical application CTDNA detection sample peripheral blood breast cancer patient , act new technique indicator early diagnosis , therapy efficiency , postoperative surveillance breast cancer .</brief_summary>
	<brief_title>Clinical Application CTDNA Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Written informed consent must obtain document accord local regulatory requirement prior begin specific protocol procedure . 2 . Age least 18 70 year . 3 . Performance status ( KarnofskyIndex ) ï¼ž80 % . 4 . Chemotherapy necessary surgery . 5 . No clinical evidence local recurrence distant metastasis . 6 . Complete stag workup within 3 month prior registration . All patient must ( bilateral ) mammography breast MRI , chest Xray ; test may perform clinically indicate . 7 . Life expectancy least 2 year , disregard diagnosis cancer . 8 . Adequate organ function include normal red white blood count , platelet , serum creatinine , bilirubin , transaminase within normal range institution . 9 . Patients must available compliant treatment followup . 10 . Patients register trial must treat follow participate center . 1 . Known hypersensitivity reaction investigational compound incorporated substance . 2 . Local recurrence and/or metastasis breast cancer . 3 . No need chemotherapy . 4 . Pregnant lactating patient . Patients childbearing potential must negative pregnancy test ( urine serum ) within 14 day prior registration . Prior concomitant secondary malignancy ( except nonmelanomatous skin cancer carcinoma situ uterine cervix ) 5 . Any serious medical pathology , congestive heart failure ; unstable angina ; history myocardial infarction previous year ; uncontrolled high risk arrhythmias 6 . Other serious illness medical condition may interfere understand give informed consent conduct study . 7 . Concurrent treatment experimental drug anticancer therapy . 8 . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>ctDNA</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
</DOC>